Nebivolol, a highly selective β1-adrenergic receptor inhibitor, has vasodilatory effect so that could be effective against hypertension. It was just withdrawed a Phase II/III trial for Hypertension in patients with chronic obstructive pulmonary disease.
https://www.bocsci.com/l-nebivolol-cas-118457-14-0-item-82193.html